Cost of persistent asthma in Italy

Negro, Roberto W. Dal; Distante, Chiara; Bonadiman, Luca; Turco, Paola; Iannazzo, Sergio

doi:10.1186/s40248-016-0080-1

Cited by 17 publications

(34 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Costs were based on the last available "2013 National Tariff Nomenclator". 26 4) GP visits for OA retrieved from Dal Negro, 2016 27 and inflated to 2019 prices according to the ISTAT consumer price index. 28 5) Joint prothesis.…”

Section: Data and Cost Sourcesmentioning

confidence: 99%

Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy

Colombo¹,

Heiman²,

Peduto³

2021

TCRM

View full text Add to dashboard Cite

Understand the demographics and clinical features of patients with osteoarthritis (OA), quantify healthcare resource utilization by OA patients, and estimate the annual direct medical costs per OA patient from a National Health Service (NHS) perspective in Italy. Patients and Methods: Retrospective observational cohort analysis using data from electronic medical records captured by the Italian IQVIA Longitudinal Patient Database (LPD). Only direct medical costs reimbursed by the NHS were considered. Patients were included if they received at least one diagnosis of OA during the period from January 1 to December 31, 2018. Each patient was observed for 3 years: a 24-month baseline period preceding the index date, and a 12-month follow-up period starting at the index date. Results: A total of 71,467 patients met inclusion criteria: 43.98% had not been prescribed NSAIDs/opioids, 40.76% had been prescribed NSAIDs, and 15.26% an opioid. Mean age was 71.36 years, and 68.2% of the patients were women. At least one comorbidity was present in 91.34% of the patients; 38.05% were newly diagnosed with OA. During 1-year of follow-up, 173,884 prescriptions with an associated diagnosis of OA were found: 47.36% had been prescribed an NSAID, 9.11% diclofenac, 8.30% codeine+paracetamol, and 7.32% ketoprofen. Nearly 15% of the patients had at least 1 request for a specialist visit and 23.82% had at least 1 request for exams. Orthopedic visits accounted for 60% of all specialist visits. Yearly mean costs per patient were €622, for approximately €2.5 billion per year in direct costs, considering 3.9 million patients with OA in Italy. Protheses were a major driver in annual costs: €143.45 in patients without a prosthesis and €10,090.91 in those with a joint prosthesis. Conclusion:This real-world analysis of direct costs of care of patients with OA in Italy confirms the substantial economic burden. Direct costs dramatically increased when joint replacement was needed.

show abstract

Section: Data and Cost Sourcesmentioning

confidence: 99%

Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy

Colombo¹,

Heiman²,

Peduto³

2021

TCRM

View full text Add to dashboard Cite

show abstract

“…Asthma is one of the most common non-communicable respiratory disease, affecting about 6% of general population, that is currently more than 300 millions of people in the world1, 2; the trend of asthma prevalence seems to be at least stable, 1 if not even increasing in the last few years 2, 3. This epidemiological situation accounts for high and increasing health-related costs (direct and indirect),4, 5, 6, 7, 8, 9 particularly in those patients with suboptimal control of asthma 10, 11…”

Section: Introductionmentioning

confidence: 99%

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

Canonica

Colombo

Bruno³

et al. 2019

World Allergy Organization Journal

View full text Add to dashboard Cite

Background Asthma is one of the most common non-communicable respiratory diseases, affecting about 6% of the general population. Severe asthma, even if afflicts a minority of asthmatics, drives the majority of costs of the disease. The aim of this study is to create a pharmacoeconomic model to predict the costs of corticosteroid-related adverse events in severe asthmatics and applying it to the first published epidemiologic data from the Severe Asthma Network in Italy (SANI) registry. Methods The analysis was conducted from the perspective of the Italian National Healthcare System (INHS). Model inputs, derived from literature, included: asthma epidemiology data, frequency of adverse events, percentage of severe asthma treated with OCS and adverse event cost (Diagnosis-Related Group (DRG) national tariffs). We estimated costs per different patient groups: non-asthma controls, mild/moderate and severe asthmatics. Final results report estimated direct cost per patient and total direct cost for overall target population, showing economic impact related to corticosteroid complication. Results Based on epidemiological data input, in Italy, asthmatic subjects resulted about 3,999,600, of which 199,980 with severe asthma. The number of patients with severe asthma OCS-treated was estimated at 123,988. Compared to the non-asthma control cohort and to that with moderate asthma annual cost per severe asthmatic patient resulted respectively about €892 and €606 higher, showing a corticosteroids shadow cost ranging from 45% to 30%. Applying the cost per patient to the target population identified for Italy, the budget impact model estimated a total annual cost related to OCS-related adverse events of €242.7 million for severe asthmatics. In respect with non-asthmatic and moderate population, an incremental expenditure of about € 110.6 million and €75.2, respectively, were shown. Conclusions Our study provides the first estimates of additional healthcare costs related to corticosteroid induced adverse events in severe asthma patient. Budget impact model results highlighted the relevant economic impact of OCS-related adverse events in severe asthma patients. The future extrapolation of additional data from SANI registry will support the development of a model to investigate the role of corticosteroids sparing drugs.

show abstract

“…Current international asthma management guidelines (Global Initiative for Asthma (GINA) - Global strategy for asthma management and prevention report 2017) define asthma control as having no or minimal daytime and nocturnal symptoms, no or minimal use of rescue bronchodilators, no acute exacerbations and normal or near-normal lung function. Nevertheless, many patients with asthma continue to live with uncontrolled symptoms leading to hospitalization, low health-related quality of life (Guilbert et al, 2011) and increased cost of treatment (Dal Negro et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Inhaler technique education and asthma control among patients hospitalized for asthma in Jordan

Basheti

Obeidat

Reddel

2018

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

ObjectivesTo investigate the effect of inhaler technique education delivered by a clinical pharmacist to patients hospitalised for asthma, on inhaler technique scores and asthma control at three months post-discharge.MethodsThis pre-post interventional study in Jordan enrolled patients who had been admitted for asthma and were using controller medication by Accuhaler [Diskus] (ACC), Turbuhaler (TH) or Pressurized metered dose inhalers (pMDI). Inhaler technique was assessed using published checklists (score 0–9). Asthma symptom control was assessed by Asthma Control Test (ACT, range 5–25). Patients were assessed on admission (baseline), pre-discharge, and 3 months later. All patients received a ‘Show-and-Tell’ inhaler technique counseling service prior to discharge.ResultsBaseline data were available for 140 patients, 71% females, mean age 52.7 (SD 16.64) years, mean ACT score 10.0 (SD 4.8). Mean inhaler score was 7.5 (SD 1.52) with no significant difference between the inhaler groups (p = 0.174). After pre-discharge training, all patients had correct technique (score 9/9). After 3 months, mean inhaler scores were significantly higher than at baseline (8.14 (SD 0.87, p < 0.001), with mean change significantly higher for TH 1.21 (SD 2.25) and ACC 0.85 (SD 0.97) than pMDI (0.16; SD 0.72), p = 0.001. Symptom control improved significantly for all patients, with a mean increase in ACT score of 7.54 (SD 8.18), with no significant difference between the inhaler device groups (p = 0.326).ConclusionsPatients hospitalized for asthma achieved correct inhaler technique after training by a pharmacist, and maintained better technique at 3 months than on admission. Significant improvements in ACT scores were documented for all inhaler groups.

show abstract

Cost of persistent asthma in Italy

Cited by 17 publications

References 3 publications

Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy

Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

Inhaler technique education and asthma control among patients hospitalized for asthma in Jordan

Contact Info

Product

Resources

About